Study of TQB3702 plus immunochemotherapy for B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new tablet (TQB3702) combined with standard immune-and-chemo therapy for certain types of B-cell lymphoma that have come back or not responded to previous treatment. It aims to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with either: slow-growing B-cell lymphoma that came back after treatment, or diffuse large B-cell lymphoma.
- You have at least one tumor that can be measured on scans.
- You are willing to use effective birth control during the study and for 6 months after.
- You have not had other cancers in the last 3 years (except some skin or cervical cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TQB2825 against standard immunotherapy for people with follicular lymphoma that has come back or not responded after at least two prior treatments. It aims to see if TQB2825 works better at controlling the lymphoma.
This trial tests a new drug called TQB2825, given as a shot under the skin, for people with certain types of blood cancer (B-cell lymphomas) that have come back or stopped responding to previous CD20 antibody treatments. The goal is to see if it is safe and works.
This trial tests an experimental oral capsule called TQB3019 for people with advanced blood cancers that have come back or not improved with other treatments. The goal is to see if the drug is safe and to find the right dose.
This trial tests an experimental drug called TQB3205 for people with advanced solid tumors that have not responded to other treatments. The study will check if the drug is safe and how it affects the tumors.
This trial tests an experimental tablet called TQB3217 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and helps shrink or control the tumor.
This trial tests a new daily tablet (TQB3911) for people with chronic myeloid leukemia (CML) whose current targeted therapy (TKI) has stopped working or caused side effects. The goal is to see if this new drug is safe and can better control the leukemia.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.